ORYZON to give updates on corporate progress in October

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that its management will give an update on corporate progress at several international events in October.

Oryzon will participate at the Chardan's 6th Annual Genetic Medicines Conference, which will be held on October 3-4 in New York (USA). The company will hold one-to-one meetings with pharmaceutical companies and global investors.Click on the link for more info about the Chardan’s 6th Annual Medicines Conference.

Oryzon will participate at the MSD European Business Development Outreach, which will be held on October 5 in Zurich (Switzerland). The company will hold one-to-one meetings with pharmaceutical companies and global investors.

Oryzon will participate at the Iberian Digital Forum on October 6-7, where the company will hold one-to- one meetings with national investors.

Oryzon will participate at the AACR Special Conference: Cancer Epigenomics in Washington (USA) on October 6-8, where the company will present a poster communication entitled: “ASCL1 and SOX2 expression levels predict sensitivity to LSD1 inhibition with iadademstat in small cell lung cancer” on October 7 at 18:00 ET. For more info about the event click on the link AACR Special Conference: Cancer Epigenomics.

Oryzon has been invited to the European Brain Council (EBC)’s annual European congress, Brain Innovation Days, which will be held on October 11-12 in Brussels (Belgium). The company will take part in a panel discussion entitled “Innovative Funding Models”, taking place on October 12 at 14:35 CEST. Click on the linke for more info about the Brain Innovation Days.

Oryzon has been invited to the HealthTech Innovation Days, which will be held on October 13-14 in Paris (France). The company will participate at a round table devoted to age-related diseases on October 13 at 11:00 CEST.  Click on the link for more information about the HealthTech Innovation Days

Oryzon will attend BIO-Europe 2022, which will be held in Leipzig (Germany) and virtually on October 24- 26, where the company will provide a corporate update and will also hold one-to-one meetings with pharmaceutical companies and global investors. Click on link for more info about BIO-Europe 2022

Finally, Oryzon will participate at the 34th EORTC-NCI-AACR Symposium, which will be held on October 26- 28 in Barcelona (Spain). The company will present two poster communications entitled "Iadademstat effects on neuroendocrine, inflamed and mesenchymal gene expression patterns in small cell lung cancer subtypes " and "Iadademstat and gilteritinib synergistically abrogate viability of both treatment-naïve and drug-resistant AML cells" on October 27. Click on link for more info about the 34º EORTC-NCI-AACR Symposium